JP7249060B2 - 抗血管新生融合タンパク質およびその使用 - Google Patents
抗血管新生融合タンパク質およびその使用 Download PDFInfo
- Publication number
- JP7249060B2 JP7249060B2 JP2021507950A JP2021507950A JP7249060B2 JP 7249060 B2 JP7249060 B2 JP 7249060B2 JP 2021507950 A JP2021507950 A JP 2021507950A JP 2021507950 A JP2021507950 A JP 2021507950A JP 7249060 B2 JP7249060 B2 JP 7249060B2
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- protein
- ang
- bifunctional
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Description
この出願は、参照によりその全体が本明細書に組み込まれる2018年8月17日に出願された米国仮出願第62/719,377号の利益およびそれに対する優先権を主張する。
本発明は、二機能性融合タンパク質である抗血管新生融合タンパク質に関する。
血管新生は、既存の血管からの発芽による血管の形成であり、固形腫瘍の増殖および腫瘍の転移に不可欠である。新しい毛細血管の生成は、元の血管の膜の溶解、内皮細胞の遊走および増殖、および新しい血管管の形成を含む多工程プロセスを含む。これらの工程のいずれかを抑制すると、新しい血管の形成が阻害され、従って腫瘍の増殖および転移の生成に影響を及ぼす。実際、単一の内皮細胞の排除が腫瘍細胞の増殖を阻害する可能性があると推定されている。抗血管新生治療は、がん処置のための有望なメカニズムを提供してもよいことが報告されている。
本明細書で他に定義されない限り、本明細書で使用される科学的および技術的用語は、当業者により一般的に理解される意味を有する。
Claims (4)
- アンジオポエチン(ANG)-TIEシグナル伝達経路および血管内皮増殖因子(VEGF)-血管内皮増殖因子受容体(VEGFR)シグナル伝達経路を阻害する二機能性融合タンパク質であって、ここで融合タンパク質はANG阻害ドメインおよびVEGF阻害ドメインを含有し、それにより、ANG、VEGF、またはその両方とそれらの受容体との間の相互作用をブロックすることを通して血管新生の阻害において有意に改善された効力を提供し、ここで該二機能性融合タンパク質は配列番号13に記載のアミノ酸配列を有する、二機能性融合タンパク質。
- 請求項1に記載の二機能性融合タンパク質および薬学的に許容される担体を含む、医薬組成物。
- 加齢性黄斑変性症(AMD)疾患を予防または処置するための、請求項2に記載の医薬組成物。
- 原発性または転移性がんを処置するための、請求項2に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862719377P | 2018-08-17 | 2018-08-17 | |
US62/719,377 | 2018-08-17 | ||
PCT/US2019/046996 WO2020037309A1 (en) | 2018-08-17 | 2019-08-19 | Anti-angiogenesis fusion protein and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021534186A JP2021534186A (ja) | 2021-12-09 |
JP7249060B2 true JP7249060B2 (ja) | 2023-03-30 |
Family
ID=69523726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021507950A Active JP7249060B2 (ja) | 2018-08-17 | 2019-08-19 | 抗血管新生融合タンパク質およびその使用 |
Country Status (6)
Country | Link |
---|---|
US (2) | US11518819B2 (ja) |
EP (1) | EP3836959A4 (ja) |
JP (1) | JP7249060B2 (ja) |
CN (1) | CN112912104A (ja) |
TW (1) | TW202021988A (ja) |
WO (1) | WO2020037309A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
US20220389120A1 (en) * | 2021-06-03 | 2022-12-08 | Gensun Biopharma Inc. | Multispecific antagonists |
WO2023028004A1 (en) * | 2021-08-23 | 2023-03-02 | Avirmax, Inc. | Compositions and methods for transgene expression |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007525187A (ja) | 2003-05-16 | 2007-09-06 | レセプター・バイオロジクス・インコーポレイテッド | イントロン融合タンパク質、ならびにその同定方法および使用方法 |
JP2010518871A (ja) | 2007-02-27 | 2010-06-03 | ジェネグゼル−セイン インク. | 成長因子と結合する融合タンパク質 |
JP2012504943A (ja) | 2008-10-08 | 2012-03-01 | エフ.ホフマン−ラ ロシュ アーゲー | 二重特異的抗−vegf/抗−ang−2抗体 |
JP2015527064A (ja) | 2012-07-13 | 2015-09-17 | ロシュ グリクアート アクチェンゲゼルシャフト | 二重特異性抗vegf/抗ang−2抗体及び眼血管疾患の処置におけるそれらの使用 |
JP2017189167A (ja) | 2011-12-01 | 2017-10-19 | エーピー バイオサイエンシーズ, インコーポレイテッド | 補体経路およびvegf経路に対するタンパク質インヒビターおよびそれらの使用方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US9914770B2 (en) | 2013-04-30 | 2018-03-13 | Intas Pharmaceuticals Ltd | Cloning, expression and purification method for the preparation of ranibizumab |
KR102060187B1 (ko) * | 2013-07-19 | 2019-12-27 | 삼성전자주식회사 | Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도 |
US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
AU2016229053B2 (en) * | 2015-03-11 | 2018-07-12 | Ap Biosciences, Inc. | Fusion protein comprising a ligand binding domain of VEGF and PDGF |
KR102155875B1 (ko) | 2015-06-28 | 2020-09-16 | 올제네시스 바이오테라퓨틱스 아이엔씨. | 혈관신생 억제용 융합 단백질 |
WO2017165681A1 (en) * | 2016-03-24 | 2017-09-28 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
EP3454903A4 (en) * | 2016-05-13 | 2020-08-19 | Askgene Pharma, Inc. | NEW ANGIOPOIETIN-2, VEGF DUAL ANTAGONISTS |
CN107602702A (zh) * | 2017-09-22 | 2018-01-19 | 生标(上海)医疗器械科技有限公司 | 一种同时靶向人p185和血管内皮生长因子的抗体及其应用 |
-
2019
- 2019-08-19 TW TW108129526A patent/TW202021988A/zh unknown
- 2019-08-19 EP EP19849871.9A patent/EP3836959A4/en active Pending
- 2019-08-19 US US16/544,648 patent/US11518819B2/en active Active
- 2019-08-19 JP JP2021507950A patent/JP7249060B2/ja active Active
- 2019-08-19 WO PCT/US2019/046996 patent/WO2020037309A1/en unknown
- 2019-08-19 CN CN201980050190.9A patent/CN112912104A/zh active Pending
-
2021
- 2021-12-14 US US17/550,694 patent/US20220169750A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007525187A (ja) | 2003-05-16 | 2007-09-06 | レセプター・バイオロジクス・インコーポレイテッド | イントロン融合タンパク質、ならびにその同定方法および使用方法 |
JP2010518871A (ja) | 2007-02-27 | 2010-06-03 | ジェネグゼル−セイン インク. | 成長因子と結合する融合タンパク質 |
JP2012504943A (ja) | 2008-10-08 | 2012-03-01 | エフ.ホフマン−ラ ロシュ アーゲー | 二重特異的抗−vegf/抗−ang−2抗体 |
JP2017189167A (ja) | 2011-12-01 | 2017-10-19 | エーピー バイオサイエンシーズ, インコーポレイテッド | 補体経路およびvegf経路に対するタンパク質インヒビターおよびそれらの使用方法 |
JP2015527064A (ja) | 2012-07-13 | 2015-09-17 | ロシュ グリクアート アクチェンゲゼルシャフト | 二重特異性抗vegf/抗ang−2抗体及び眼血管疾患の処置におけるそれらの使用 |
Non-Patent Citations (1)
Title |
---|
Accession No.Q02763,Database UniProt [online],2018年06月20日,https://www.uniprot.org/uniprot/Q02763.txt?version=204, [retrieved on 2022.5.10] |
Also Published As
Publication number | Publication date |
---|---|
JP2021534186A (ja) | 2021-12-09 |
WO2020037309A1 (en) | 2020-02-20 |
US20200055958A1 (en) | 2020-02-20 |
US11518819B2 (en) | 2022-12-06 |
CN112912104A (zh) | 2021-06-04 |
EP3836959A1 (en) | 2021-06-23 |
TW202021988A (zh) | 2020-06-16 |
US20220169750A1 (en) | 2022-06-02 |
EP3836959A4 (en) | 2022-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7249060B2 (ja) | 抗血管新生融合タンパク質およびその使用 | |
JP7348249B2 (ja) | Vegf-grabタンパク質と薬物の結合体及びその用途 | |
US11192927B2 (en) | Fusion proteins for inhibiting angiogenesis | |
ES2379662T3 (es) | Anticuerpos contra factor de crecimiento de tejido conjuntivo | |
WO2019062642A1 (zh) | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 | |
US9856462B2 (en) | Method of treating eye disease using glycosylated VEGF decoy receptor fusion protein | |
CA2913126C (en) | Anti-vegf antibody and pharmaceutical composition for prevention, diagnosis or treatment of cancer or angiogenesis-related disease containing the same | |
WO2020143720A1 (zh) | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 | |
US20200115443A1 (en) | Bi-functional fusion proteins and uses thereof | |
RU2652880C2 (ru) | Антитело против рецептора эпидермального фактора роста | |
JP7119225B2 (ja) | Pdgf受容体に対する抗体およびその用途 | |
Chakrabarti | Functionality determination and characterization of an angiogenesis-inhibiting fusion protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210415 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220517 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220816 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221014 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230214 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230310 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7249060 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |